天演药业Adagene | DJSeedin创新合作峰会上市公司路演汇报

天演药业（纳斯达克股票代码：ADAG）是平台驱动并拥有自主平台产出的临床产品开发阶段的生物制药公司，公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。 

借助计算生物学和人工智能相结合的强大平台，天演药业研制出高安全性和有效性的新型抗体，为更多癌症患者带来了福音。

天演药业的抗体发现引擎——“动态精准抗体库”（Dynamic Precision Library），正在推动天演药业的产品管线开发，致力于打造潜在的全球创新或同类最佳型产品。

天演已经与多家知名的全球公司建立了战略合作伙伴关系。这些合作伙伴充分利用天演的前沿技术，如更安全的精确靶向抗体偶联药物（antibody-drug conjugate, ADC）及创新抗体设计。在精准抗体工程研发领域拥有世界一流水平的核心团队领导下，天演致力于为久而未结的治疗挑战提供全新的解决方案。

Adagene is a Nasdaq listed, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer.

Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients. 

Our discovery engine, Dynamic Precision Library, is driving Adagene’s pipeline of programs with potential to be first or best in class.

We have forged strategic partnerships with multiple reputable global companies. These partnerships leverage our technology in approaches at the vanguard of science, including safer precision-guided antibody-drug conjugates and transformative antibody design.

Founded and led by world-class leaders in antibody discovery and engineering, Adagene is well-positioned to address unmet needs in areas where other treatments have had little or no success.